Literature DB >> 22727970

Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease.

Marieke A Hillaert1, Eef G Lentjes, Hans Kemperman, Yolanda van der Graaf, Hendrik M Nathoe, Farzin Beygui, Gilles Montalescot, Pieter A Doevendans, Annemarie M Wassink, Eric van Belle.   

Abstract

BACKGROUND AND AIMS: Plasma aldosterone has been associated with all-cause and cardiovascular mortality in high-risk cardiovascular populations, including patients with heart failure, myocardial infarction and high-risk coronary artery disease (CAD) patients. In the present study, we evaluated the association of plasma aldosterone levels with vascular events in a large prospective cohort of stable CAD patients recruited in an outpatient setting. Moreover, we investigated the relationship between aldosterone and atherosclerotic burden. METHODS AND
RESULTS: Baseline plasma aldosterone levels were measured in 2699 subjects with CAD (mean age 60 ± 10 years, 82% male). During a median follow-up of 4.7 years, 308 (11%) patients died, of which 203 were from a vascular cause. Vascular endpoints of myocardial infarction, ischemic stroke or vascular death occurred in 355 (13%) patients. Multivariable Cox regression analysis was performed, adjusting for multiple confounders. Aldosterone (median 96 pg/mL, interquartile range 70-138 pg/mL, normal range 58-362 pg/mL) was independently associated with major vascular events (hazard ratio (HR) 1.56, 95% confidence interval (CI) 1.13-2.15) and vascular mortality (HR 1.95, 95% CI 1.27-3.00). By multivariable regression analysis, aldosterone was also associated with the presence of atherosclerosis in additional vascular territories (cerebrovascular disease and/or peripheral artery disease) (p=0.026).
CONCLUSIONS: In patients with stable coronary artery disease, plasma aldosterone is independently associated with the risk of major vascular events and vascular mortality and with atherosclerotic burden.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aldosterone; Atherosclerosis; Coronary artery disease; Mortality; Risk factors

Mesh:

Substances:

Year:  2012        PMID: 22727970     DOI: 10.1016/j.ijcard.2012.05.034

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

Review 1.  Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

Authors:  Adam P McGraw; Amy McCurley; Ioana R Preston; Iris Z Jaffe
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

Review 2.  Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.

Authors:  Amy McCurley; Adam McGraw; Dafina Pruthi; Iris Z Jaffe
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

Review 3.  Vascular calcification and renal bone disorders.

Authors:  Kuo-Cheng Lu; Chia-Chao Wu; Jen-Fen Yen; Wen-Chih Liu
Journal:  ScientificWorldJournal       Date:  2014-07-17

4.  End stage renal disease-induced hypercalcemia may promote aortic valve calcification via Annexin VI enrichment of valve interstitial cell derived-matrix vesicles.

Authors:  Lin Cui; Nabil A Rashdan; Dongxing Zhu; Elspeth M Milne; Paul Ajuh; Gillian Milne; Miep H Helfrich; Kelvin Lim; Sai Prasad; Daniel A Lerman; Alex T Vesey; Marc R Dweck; William S Jenkins; David E Newby; Colin Farquharson; Vicky E Macrae
Journal:  J Cell Physiol       Date:  2017-05-24       Impact factor: 6.384

5.  Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.

Authors:  Wennan Li; Xingjuan Chen; Ashley M Riley; S Christopher Hiett; Constance J Temm; Eleni Beli; Xin Long; Saikat Chakraborty; Mouhamad Alloosh; Fletcher A White; Maria B Grant; Michael Sturek; Alexander G Obukhov
Journal:  Basic Res Cardiol       Date:  2017-07-29       Impact factor: 17.165

6.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study.

Authors:  Kennosuke Ohashi; Takeshi Hayashi; Yui Watanabe; Koichiro Hara; Rikako Ukichi; Hiroshi Asano; Hirofumi Suzuki; Kenji Yamashiro; Katsuyoshi Tojo; Masaya Sakamoto; Kazunori Utsunomiya
Journal:  J Clin Med Res       Date:  2017-12-01

7.  Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism.

Authors:  Adam P McGraw; Jessamyn Bagley; Wei-Sheng Chen; Carol Galayda; Heather Nickerson; Andrea Armani; Massimiliano Caprio; Peter Carmeliet; Iris Z Jaffe
Journal:  J Am Heart Assoc       Date:  2013-02-22       Impact factor: 5.501

8.  Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke.

Authors:  Quynh N Dinh; Thiruma V Arumugam; Morag J Young; Grant R Drummond; Christopher G Sobey; Sophocles Chrissobolis
Journal:  Exp Transl Stroke Med       Date:  2012-10-30

9.  Relationship of renin-angiotensin-aldosterone system polymorphisms and phenotypes to mortality in Chinese coronary atherosclerosis patients.

Authors:  En-Zhi Jia; Zhao-Hong Chen; Feng-Hui An; Li-Hua Li; Chang-Yan Guo; Yan Gu; Zhe Liu; Zhao-Yang Li; Tie-Bing Zhu; Lian-Sheng Wang; Chun-Jian Li; Xiang-Qing Kong; Wen-Zhu Ma; Zhi-Jian Yang
Journal:  Sci Rep       Date:  2014-04-11       Impact factor: 4.379

10.  Aldosterone-to-Renin Ratio Is Associated With Reduced 24-Hour Heart Rate Variability and QTc Prolongation in Hypertensive Patients.

Authors:  Martin R Grübler; Katharina Kienreich; Martin Gaksch; Nicolas Verheyen; Bríain Ó Hartaigh; Astrid Fahrleitner-Pammer; Winfried März; Johannes Schmid; Eva-Maria Oberreither; Julia Wetzel; Cristiana Catena; Leonardo A Sechi; Burkert Pieske; Andreas Tomaschitz; Stefan Pilz
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.